Products Pass or Are Deemed to Pass Consistency Evaluation

1. Qidu Pharma’s Osowei® - Omeprazole Sodium Bicarbonate Dry Suspension (I) Approved for Market Launch
2.Jisu® - Sodium Bicarbonate Injection (all specifications) pass evaluation, marking Qidu Pharma’s integrated development of APIs + formulations.

3.Qidu Pharma’s Antitumor Drug Yinite® - Ibrutinib Capsules Approved for Production
4.Qidu Pharma’s New Anti-Anaerobic Drug Morinidazole API and Injection Approved for Market Launch
5.Dihuanxin™ - Ciprofloxacin Lactate and Sodium Chloride Injection Passes Consistency Evaluation
6.Qiheng® - Compound Sodium Acetate Ringer’s Injection Passes National Consistency Evaluation
7.Qinengtai® - Pentoxifylline Injection Approved for Market Launch and Deemed to Pass Consistency Evaluation
8.Anpulan® - Lanthanum Carbonate Chewable Tablets Approved for Market Launch and Deemed to Pass Generic Drug Consistency Evaluation
9.Puruitai® - Paracetamol Tablets Approved for Market Launch and Deemed to Pass Consistency Evaluation